Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    19 July 2023

    ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

    Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Lead molecule ARM210 repairs ‘leaky’ Ryanodine Receptor (RyR) channels to restore intracellular calcium signaling in cardiac and musculoskeletal di...

    17 July 2023

    Nitrite screening in the Pharmaceutical Industry: The Power of the ATNA System

    In the world of pharmaceutical manufacturing and quality assurance, nitrites have been identified as a considerable concern. With the requirements to complete risk assessments for product lines for the risk of nitrosamine contamination.  These chemical compounds have been identifie...

    29 June 2023

    Exploring the Differences: Manual vs. Automated Challenge Chemical Introduction in Permeation Testing

    In the world of permeation testing, the choice between manual and automated challenge chemical introduction can significantly impact the efficiency and automation capabilities of the testing process. This article will delve into the key differences between these two approaches and highl...

    22 June 2023

    Automated Apparent Total Nitrosamine Analysis for the Carbon Capture Industry

    Absorption, or carbon scrubbing, with amines is the most widely used commercial system for the removal of carbon dioxide (CO2) from the exhaust of chemical plants, biomass plants or from burning fossil fuels.  Carbon capture is seen as one of the main ways to reduce CO2 to net zero...

    19 July 2023

    H.E.L Group signs agreement with Indian Institute of Technology (IIT) Kanpur in national initiative for sustainable energy

    H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced it has signed an agreement with the Indian Institute of Technology Kanpur (IIT Kanpur), a prestigious Indian academic institution kicks...

    18 July 2023

    Arrayjet announces collaboration with Chemspace to augment its small molecule microarray services for drug discovery

    Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that it has partnered with Chemspace, the largest online catalogue of small molecules and biologics, to augment and streamline the Company’s small molecule microarray (SMM) service offering. Chemspace’s cu...

    17 July 2023

    PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board

    Experts in translational oncology and targeted protein degradation join Dr Simon Cook, Dr Lorenz Mayr and Dr Catherine Beech to provide scientific and strategic oversight ...

    7 February 2023

    Spinout develops open-source software for the pharmaceutical industry

    A group of university research scientists has formed a startup to adapt open-source academic chemical software for use in the pharmaceutical industry. ...

    17 July 2023

    Corazon Health's OHA Days took place last week

    Last week Corazon Health celebrated their OHA Days - an annual event which aims to provide additional training to employees through workshops, debates and question-and-answer sessions. It is also an excellent opportunity for all staff to get together and take part in team building ...

    13 July 2023

    Office of Life Sciences Healthtech Survey

    The impact that the HealthTech industry has on patients, and health systems, is well recognised. But its economic footprint, through the creation of high quality jobs, and vibrant regional clusters, is less understood. Therefore, the Office of Life Sciences (OLS) have commiss...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 187
    • Page 188
    • Current page 189
    • Page 190
    • Page 191
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS